Recall Reminder: Gerber Products Company Previously Recalled and Discontinued All Batches of Gerber® Soothe N Chew® Teething Sticks Due To Potential Choking Hazard
We are issuing a second press release about this recall due to recent reports of product still on still available for sale on some retailer shelves and online. The previous announcement from January 31 is linked here and on FDA's recall page.
GERBER® SOOTHE N CHEW® TEETHING STICKS were distributed nationwide.
Recalled products can be identified as follows:
Gerber® Soothe N Chew® Teething Sticks - Product Packaging
The previously issued recall and discontinuation is isolated to GERBER® SOOTHE N CHEW® TEETHING STICKS – STRAWBERRY APPLE and GERBER® SOOTHE N CHEW® TEETHING STICKS – BANANA.
The recall was initiated after receiving consumer complaints of choking incidents.
Consumers who may have purchased GERBER® SOOTHE N CHEW® TEETHING STICKS should not feed this product to their child and can return the product to the retailer where it was purchased for a full refund. Consumers who find the product for sale in the market should not purchase the product. Anyone with health concerns should contact a health care provider. For any additional support needed, Gerber is available 24/7 at 1-800-4-GERBER (1-800-443-7237).
We have been working with the U.S. Food & Drug Administration (FDA) on this recall and will cooperate with them fully.
Again, we sincerely apologize for any concern or inconvenience this action represents to parents, caregivers and retail customers.
Media Contact:
Lauren Rubbo
[email protected]
703-682-7748
View original content to download multimedia: https://www.prnewswire.com/news-releases/recall-reminder-gerber-products-company-previously-recalled-and-discontinued-all-batches-of-gerber-soothe-n-chew-teething-sticks-due-to-potential-choking-hazard-302432460.html
SOURCE Nestlé USA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
29 minutes ago
- Associated Press
Say Goodbye to Itchy Skin: SilverCeuticals Launches Breakthrough FDA-Registered Eczema Therapy & Skin Relief Cream
The natural solution to skin irritation - Powered by science, nature, and silver. LINDON, UTAH / ACCESS Newswire / August 19, 2025 / SilverCeuticals Inc, a leader in advanced nano silver health and wellness solutions, is proud to announce the launch of its newest FDA-registered Over the Counter (OTC) drug product: Eczema Therapy & Skin Relief Cream. Designed to deliver fast, effective relief for irritated skin, this revolutionary formula combines FDA-approved colloidal oatmeal with SilverCeuticals' AG4O4 Nano Silver Therapy & Skin Relief Cream A bottle of SilverCeuticals Eczema Therapy & Skin Relief Cream Clinically backed, naturally soothing, and powerfully effective. Visible results may be seen in just 1-2 days. 'It's time for eczema relief products that actually work, without harsh chemicals,' said Dr. Keith Moeller, CEO of SilverCeuticals. 'This product is safe, highly moisturizing, and supports fast recovery for children and adults who suffer from eczema and other skin irritations. We've included ingredients that not only meet FDA standards but also align with the values of natural health practitioners.' This ultra-hydrating cream features a powerful blend of ingredients, including: Unlike many conventional treatments, this formulation is free from steroids, parabens, fragrances, and other harsh chemicals - making it ideal for sensitive skin. It also provides relief beyond eczema for other common skin issues, such as: Packaged in a TSA-compliant 3.4 oz. airless pump bottle, it's perfect for travel and daily use. 'One in five children experiences eczema and our goal is to eliminate their irritation and suffering without the harmful side effects. We believe healing should be fast, safe, and accessible.' added Dr. Moeller. 'After just two days, my son's eczema patches had nearly disappeared. Nothing has ever worked this fast and without steroids.' - Sarah L., mother of a 6-year-old eczema sufferer AG4O4 Nano Silver has been shown in lab studies to support the body's natural healing process and helps reduce inflammation at the source. Experience real relief! Order your first bottle today at Use the coupon code 'Heal' to receive a 15% discount at checkout. Also available through practitioners, professionals, and affiliates. For media or wholesale inquiries, contact SilverCeuticals at 385-212-4044. Contact InformationKirk Moeller CMO 8016364851 SOURCE: SilverCeuticals Inc press release
The Hill
30 minutes ago
- The Hill
Copycat Ozempic, Mounjaro proliferate even in postshortage era
Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some experts saying 'regulatory neglect' is allowing for potentially dangerous, unapproved drugs to reach consumers. When the Food and Drug Administration (FDA) adds a drug to its official shortage list, compounding pharmacies can sell their own versions of that drug so patients can continue to access medications. This was the case when weight loss drugs like tirzepatide and semaglutide went into shortage due to high demand. Online companies like Hims & Hers and Ro entered the GLP-1 market with compounded versions of Wegovy and Zepbound. These medications contain the same active pharmaceutical ingredient as the branded version but are formulated slightly differently, such as altering a medication for a patient who can't swallow pills. Due to the often highly individualized nature of compounded drugs, they are not FDA-approved. But although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold, and lawmakers in Congress have begun raising concerns with federal regulators. There are two types of compounding pharmacies, 503A and 503B. 503A compounding pharmacies fulfill personalized, patient-specific prescriptions. 503B compounding pharmacies can do the same while also fulfilling bulk orders for clients like hospitals. Prior to the end of the shortage, telehealth companies primarily relied on 503B compounders, but according to those in the drug space, online sellers are turning to 503A compounders to keep the lucrative business going. Novo Nordisk, the manufacturer of semaglutide, partnered with Hims & Hers to sell a low-cost version of its branded product Wegovy after the shortage officially ended. But that partnership was dissolved after Novo Nordisk accused Hims & Hers of illegally continuing to sell compounded versions of its drug 'under the false guise of personalization.' Experts in the field say the maneuver falls into a regulatory 'gray area.' 'I hesitate to even call these people compounders. Because what they really are are illegal pharmaceutical companies,' said Peter Pitts, former FDA associate commissioner and president of the Center for Medicine in the Public Interest. 'You don't compound for tens of millions of people, and you don't personalize for tens of millions of people. That's just kind of a fake brand extension.' In July, a bipartisan coalition of House lawmakers sent a letter to FDA Commissioner Marty Makary asking that he direct his agency to address the flow of illicit anti-obesity medications (AOM) into the country. While not specifically focused on compounded drugs, the letter did note the possibility for ambiguity between these medications and illicitly sourced drugs. 'We understand the distinction between legitimate compounded drugs prepared in state-licensed pharmacies and counterfeit or compounded drugs made from illicit ingredients obtained from illegitimate sources,' wrote the lawmakers. 'However, unapproved AOMs continue to be widely marketed online, in print, and on television.' Sen. Marsha Blackburn (R-Tenn.) sent a letter to the Federal Trade Commission in July, calling for the agency's action on online advertising of compounded GLP-1s. She was reiterating warnings that a bipartisan group of state attorneys general had made. 'Amid the unprecedented demand for these miracle medicines, foreign criminals and con artists are defrauding and endangering Americans by selling and shipping counterfeit or deceptively-marketed GLP-1 drugs and active ingredients,' she wrote. A spokesperson for Ro said the company 'does not market or advertise compounded GLP-1s.' The Hill was able to find a half-dozen lower-profile companies still marketing compounded GLP-1s online. Hims & Hers, perhaps the most well-known of these online companies, disputed Pitt's characterization. 'Anyone claiming that we compound personalized medications for tens of millions of people is simply wrong and is mischaracterizing our business. We follow the carefully written compounding regulations and only offer access to compounded treatments when a licensed provider determines it is clinically necessary, in their independent judgment, for their individual patient,' the company said in a statement to The Hill. 'That's the future of healthcare: a system centered on the individual where providers have a way to treat the individual in front of them.' The Federal Trade Commission declined to comment as its investigations are nonpublic. The FDA did not respond to a request for comment. Pitts expressed incredulity that federal regulators hadn't stepped in already, saying, 'How long can the FDA permit kind of regulatory neglect, to allow this problem just to snowball until they get engaged?' Although the continued sale of compounded GLP-1s falls into a regulatory gray area, Pitts believes it goes against the 'spirit' of the regulations. He further cited the '5 percent rule' for compounding pharmacies, which dictates that the percentage of compounded drugs that a pharmacy distributes out of state not exceed 5 percent, saying online sellers have exceeded this rule by '10,000-fold.' According to recent polling, consumers are concerned about where compounded drugs originate from. A poll conducted by the firm Fabrizio Ward, run by President Trump's 2024 campaign pollster Tony Fabrizio, found that 64 percent of surveyed voters don't believe compounders should be able to continue to make drugs outside of the current legally permitted circumstances. Voters in the survey were split when asked how confident they were that online pharmacies sold safe, FDA-approved drugs, with 46 percent saying they were confident and 41 percent saying they were not. A majority of voters — 78 percent — said they had concerns about bulk, compounded versions of drugs like Wegovy and Zepbound coming into the U.S. from overseas sources. During the active shortage of GLP-1 products, questions were raised over where compounding pharmacies were sourcing the active pharmaceutical ingredients for their products. Telehealth companies have said their products come from FDA-regulated facilities. 'There's a difference between a product being made in an FDA-approved facility and a product being manufactured on an FDA-approved line for that product,' said Pitts. 'The FDA does not inspect production lines for illegal manufacturing, that just does not happen. So, it's an entirely fake proposition.'
Bloomberg
31 minutes ago
- Bloomberg
Right to Try Movement Finds Powerful Allies Under Trump
Hi, it's Gerry and Bob in New York. The FDA's sudden reversal on a controversial gene therapy is a sign that the right to try movement still has influence in Trump's second term. More on that in a minute, but first ... Back in 2018, Jordan McLinn, a young boy with a rare muscle disorder, was photographed hugging Donald Trump as the president signed the Right to Try law aimed at making it easier for dying patients to access experimental drugs.
